[Histological and immunohistochemical characteristics of stimulated angiogenesis in transplantation of multipotent stem cells derived from the adipose tissue in patients with chronic ischemia of the extremities].
Poliachenko IuV., Driuk MF., Dombrovs'kyĭ DB.
Prospective Study, published in Klin Khir (2010) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- Klin Khir (2010)
- Country
- Ukraine
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 20623978
Abstract (original English)
The cellular technologies application with the objective for the processes of angiogenesis stimulation, in the ischemia conditions, constitutes an actual task for modern stage of a science development, the discovery of a new sources of cells-stimulants for neoangiogenesis is in a progress. The investigation was performed with an objective of studying of histological and immunohistochemical changes in muscular tissue, occurring after autotransplantation of multipotent stromal cells from adipose tissue of the patients, suffering the extremity ischemia. Histological and immunohistochemical investigations (detection of antibodies expression towards Villebrand factor, collagen type IV and vimentin) of processes, occurring in muscular tissue after introduction of multipotent stromal cells from adipose tissue of this patient, were conducted. The reduction of myofibrils ischemic affection and rapid activation of the muscle regenerative potential were shown. There was established a vivid stimulation of the angiogenesis processes during already first month after cellular transplantation performance.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.